CLOs on the Move

Ionis Pharmaceuticals

www.ionispharma.com

 
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for ...
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details
Michael Henry
 Director of Compliance and Legal Counsel Profile
Mallorie Klemens
 Director, Legal and Associate General Counsel Profile
Matthew Buck
 Vice President, Regulatory Affairs Profile

Similar Companies

Advanz Pharma

Advanz Pharma Corp. is a multinational pharmaceutical company headquartered in London.

Amylyx

Amylyx is a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. Guided by our core values, we incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors and organizations. We work collaboratively across everything we do to positively impact the lives of patients and their families.

Accumedscript

Accumedscript is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UI Magic

UI Magic Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Visus Therapeutics

Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.